HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Core Insights - HeartSciences has received approval from the Centers for Medicare & Medicaid Services (CMS) for reimbursement of its AI-ECG technology under the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule, which is a significant milestone for the commercialization of its products [1][2] - The reimbursement payment rate for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm is expected to be $125, contingent upon FDA clearance [1] - The company aims to enhance the clinical utility of ECGs through innovative AI-based technology, targeting improvements in cardiac screening, particularly in frontline clinical settings [2] Company Overview - Heart Test Laboratories, Inc., operating as HeartSciences, focuses on applying AI technology to ECGs to improve their diagnostic capabilities and expand their clinical utility [2] - The company possesses one of the largest libraries of AI-ECG algorithms and is developing solutions that can be deployed on a cloud-based platform or its proprietary MyoVista® wavECG™ device [2] - The MyoVista® product is designed to provide both conventional ECG information and diagnostic insights related to cardiac dysfunction, traditionally available only through cardiac imaging [2]